Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality

被引:3
|
作者
Na, Hee Young [1 ]
Kim, Jee Hyun [2 ]
Kim, Haeryoung [3 ]
Cho, Jai Young [4 ]
Han, Ho-Seong [4 ]
Jang, Eun Sun [5 ]
Kim, Jin-Wook [5 ]
Jeong, Sook-Hyang [5 ]
Heo, Jayoon [2 ,6 ]
Kim, Ji-Won [2 ]
Kim, Jin Won [2 ]
Ahn, Soomin [1 ,7 ,8 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Coll Med, Seongnam, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Hematol & Med Oncol,Bundang Hosp, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul Natl Univ Hosp, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Surg, Seongnam, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Gastroenterol,Bundang Hosp, Seongnam, South Korea
[6] Ilsan Hosp, Dept Internal Med, Natl Hlth Insurance Serv, Goyang, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea
[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, 81 Irwon ro, Seoul 06351, South Korea
关键词
combined hepatocellular-cholangiocarcinoma; intermediate cell carcinoma; liver; next-generation sequencing; CARCINOMA;
D O I
10.1111/his.15081
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare type of liver tumour that exhibits both hepatocytic and biliary differentiation within the same tumour. The histology and genomic alterations of recurrent/metastatic cHCC-CC are poorly understood. We selected six patients with cHCC-CC whose recurrent or metastatic tumours were histologically confirmed. Four patients with classic cHCC-CCs and two with intermediate cell carcinomas (ICs) were included. The clinicopathological features were evaluated, and next-generation sequencing was performed in 17 multiregional and longitudinal tumour samples. The histology of recurrent/metastatic lesions of classic cHCC-CCs was variable: hepatocellular carcinoma (HCC) was observed in one (25.0%) patient, cHCC-CC in one (25.0%) patient, and cholangiocarcinoma (CC) in two (50.0%) patients. Among 13 samples from four classic cHCC-CC patients, the most frequent pathological variants were TP53 (46.2%), TERT promoter (38.5%), ARID1A mutations (23.1%), and MET amplification (30.8%). In the sequencing analysis of each HCC and CC component, three (75.0%) of the four classic cHCC-CCs shared pathogenic variants. A large proportion of mutations, both pathogenic and those of undetermined significance, were shared by each HCC and CC component. Regarding ICs, the ATM mutation was detected in one patient. In conclusion, the histology of recurrent/metastatic cHCC-CCs was heterogeneous. Genomic profiling of classic cHCC-CCs revealed similar genomic alterations to those of HCC. Considerable overlapping genomic alterations in each HCC and CC component were observed, suggesting a monoclonal origin. Genetic alterations in ICs were different from those in either HCC or CC, suggesting the distinct nature of this tumour. The histology of recurrent/metastatic tumours of cHCC-CCs was variable. Genomic profiling of cHCC-CC revealed considerable overlapping genomic alterations in each HCC and CC component.image
引用
收藏
页码:402 / 408
页数:7
相关论文
共 50 条
  • [21] Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma: A Western Experience
    Nazario Portolani
    Gian Luca Baiocchi
    Arianna Coniglio
    Tullio Piardi
    Luigi Grazioli
    Anna Benetti
    Andrea Ferrari Bravo
    Stefano Maria Giulini
    Annals of Surgical Oncology, 2008, 15 : 1880 - 1890
  • [22] Combined Hepatocellular-Cholangiocarcinoma With Ductal Plate Malformation Pattern: A Case Report With Molecular Analysis
    Moon, Woo Sung
    Song, Ji Soo
    Yu, Hee Chul
    Kim, Kyoung Min
    Ahn, Ae Ri
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2024, 32 (01) : 160 - 164
  • [23] Combined hepatocellular-cholangiocarcinoma An analysis of clinicopathological characteristics after surgery
    Zhang, Hao
    Yu, Xiaojiong
    Xu, Jian
    Li, Juan
    Zhou, Yao
    MEDICINE, 2019, 98 (38)
  • [24] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA: AN INDICATION FOR LIVER TRANSPLANTATION?
    Schaefer, I. -M.
    Reinecke, J. A.
    Goralczyk, A.
    Schultze, F. C.
    Amanzada, A.
    Schweyer, S.
    Lorf, T.
    Obed, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 39
  • [25] Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies
    Gurzu, Simona
    Szodorai, Rita
    Jung, Ioan
    Banias, Laura
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (05)
  • [26] EXPRESSION OF ABH AND LEWIS BLOOD-GROUP ANTIGENS IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - POSSIBLE EVIDENCE FOR THE HEPATOCELLULAR ORIGIN OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    OKADA, Y
    JINNO, K
    MORIWAKI, S
    MORICHIKA, S
    TORIGOE, SI
    ARIMA, T
    NAGASHIMA, H
    KOPROWSKI, H
    CANCER, 1987, 60 (03) : 345 - 352
  • [27] Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki, M.
    Sato, Y.
    Nakanuma, Y.
    HISTOPATHOLOGY, 2022, 80 (05) : 859 - 868
  • [28] Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma
    Zhao, Linghao
    Wang, Yuyouye
    Tian, Tao
    Rao, Xinjie
    Dong, Wei
    Zhang, Jinmin
    Yang, Yuan
    Tao, Qifei
    Peng, Fang
    Shen, Chenhang
    Wang, Songbo
    Liu, Hui
    Zeng, Xi
    Zhou, Weiping
    HEPATOLOGY INTERNATIONAL, 2022, 16 (06) : 1339 - 1352
  • [29] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1137 - 1139
  • [30] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1137 - 1139